Advertisement

Targeting of BAFF and APRIL for Autoimmunity and Oncology

  • Maureen C. Ryan
  • Iqbal S. Grewal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)

Abstract

BLyS and APRIL are tumor necrosis factor superfamily members shown to be important for B-cell development, maturation and survival. Recent data also indicate that these cytokines regulate the survival and maintenance of malignant B-cells in cancer patients. The key role of BlyS/APRIL in the immune system and their potential role in cancers have attracted the attention of basic scientistis and biotechnology companies alike. As a result, the pathways regulated by BLYS and APRIL have been quickly elevated as attractive targets for antibody-based and non-antibody based therapeutics. Exploitation of these pathways has not only given us enormous insights into the basic biology of the APRIL/BLyS system but it has also identified potential clinical candidates for cancer and autoimmunity. As such, multiple biotechnology companies are currently testing various therapeutic candidates in the clinic. This chapter will review BLyS and APRIL functions and discuss alternative therapeutic approaches to target BLyS and APRIL pathways for human malignancies and autoimmunity.

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Tumor Necrosis Factor Family Tumor Necrosis Factor Superfamily APRIL Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B-lymphocyte stimulator. Science 1999; 285:260–263.PubMedCrossRefGoogle Scholar
  2. 2.
    Mukhopadhyay A, Ni J, Zhai Y et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274:15978–15981.PubMedCrossRefGoogle Scholar
  3. 3.
    Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med 1999; 189:1747–1756.PubMedCrossRefGoogle Scholar
  4. 4.
    Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65:680–683.PubMedGoogle Scholar
  5. 5.
    Hahne M, Kataoka T, Schroter M et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188:1185–1190.PubMedCrossRefGoogle Scholar
  6. 6.
    Rennert P, Schneider P, Cachero TG et al. A soluble form of B-cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192:1677–1684.PubMedCrossRefGoogle Scholar
  7. 7.
    Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B-and T-cell immunity. J Clin Invest 2002; 109:1587–1598.PubMedGoogle Scholar
  8. 8.
    Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97:198–204.PubMedCrossRefGoogle Scholar
  9. 9.
    Scapini P, Nardelli B, Nadali G et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197:297–302.PubMedCrossRefGoogle Scholar
  10. 10.
    Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BlyS and APRIL. Nat Immunol 2002; 3:822–829.PubMedCrossRefGoogle Scholar
  11. 11.
    Scapini P, Carletto A, Nardelli B et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflamatory diseases. Blood 2005; 105:830–837.PubMedCrossRefGoogle Scholar
  12. 12.
    Gorelik L, Gilbride K, Dobles M et al. Normal B-cell homeostasis requires B-cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198:937–945.PubMedCrossRefGoogle Scholar
  13. 13.
    Moreaux J, Cremer FW, Reme T et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106:1021–1030.PubMedCrossRefGoogle Scholar
  14. 14.
    Ohata J, Zvaifler NJ, Nishio M et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B-cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174:864–870.PubMedGoogle Scholar
  15. 15.
    Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169:4314–4321.PubMedGoogle Scholar
  16. 16.
    Lopez-Fraga M, Fernandez R, Albar JP et al. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001; 2:945–951.PubMedCrossRefGoogle Scholar
  17. 17.
    Kolfschoten GM, Pradet-Balade B, Hahne M et al. TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol 2003; 66:1427–1432.PubMedCrossRefGoogle Scholar
  18. 18.
    Pradet-Balade B, Medema JP, Lopez-Fraga M et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002; 21:5711–5720.PubMedCrossRefGoogle Scholar
  19. 19.
    Gavin AL, Ait-Azzouzene D, Ware CF et al. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B-cell survival cytokine, BAFF. J Biol Chem 2003; 278:38220–38228.PubMedCrossRefGoogle Scholar
  20. 20.
    Gavin AL, Duong B, Skog P et al. DeltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005; 175:319–328.PubMedGoogle Scholar
  21. 21.
    Marsters SA, Yan M, Pitti RM et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10:785–788.PubMedCrossRefGoogle Scholar
  22. 22.
    Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995–999.PubMedCrossRefGoogle Scholar
  23. 23.
    Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293:2108–2111.PubMedCrossRefGoogle Scholar
  24. 24.
    Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B-cells through a BCMA-independent pathway. Science 2001; 293:2111–2114.PubMedCrossRefGoogle Scholar
  25. 25.
    Schneider P, Takatsuka H, Wilson A et al. Maturation of marginal zone and follicular B-cells requires B-cell activating factor of the tumor necrosis factor family and is independent of B-cell maturation antigen. J Exp Med 2001; 194:1691–1697.PubMedCrossRefGoogle Scholar
  26. 26.
    Yan M, Marsters SA, Grewal IS et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000; 1:37–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Wu Y, Bressette D, Carrell JA et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275:35478–35485.PubMedCrossRefGoogle Scholar
  28. 28.
    Yu G, Boone T, Delaney J et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1:252–256.PubMedCrossRefGoogle Scholar
  29. 29.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  30. 30.
    Mackay F, Silveira PA, Brink R. B-cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19:327–336.PubMedCrossRefGoogle Scholar
  31. 31.
    Ingold K, Zumsteg A, Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201:1375–1383.PubMedCrossRefGoogle Scholar
  32. 32.
    Hendriks J, Planelles L, de Jong-Odding J et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12:637–648.PubMedCrossRefGoogle Scholar
  33. 33.
    Tardivel A, Tinel A, Lens S et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B-cell survival but not for the marginal zone B-cell differentiation activity of BAFF. Eur J Immunol 2004; 34:509–518.PubMedCrossRefGoogle Scholar
  34. 34.
    Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B-cell development and autoimmune disease. Impaired B-cell maturation in mice lacking BLyS. Immunity 2001; 15:289–302.PubMedCrossRefGoogle Scholar
  35. 35.
    Thompson JS, Schneider P, Kalled SL et al. BAFF binds to the tumor necrosis factor receptor-like molecule B-cell maturation antigen and is important for maintaining the peripheral B-cell population. J Exp Med 2000; 192:129–135.PubMedCrossRefGoogle Scholar
  36. 36.
    Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B-lymphocyte stimulator that is mutated in a mouse strain with severe B-cell deficiency. Curr Biol 2001; 11:1547–1552.PubMedCrossRefGoogle Scholar
  37. 37.
    Seshasayee D, Valdez P, Yan M et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18:279–288.PubMedCrossRefGoogle Scholar
  38. 38.
    Yan M, Wang H, Chan B et al. Activation and accumulation of B-cells in TACI-deficient mice. Nat Immunol 2001; 2:638–643.PubMedCrossRefGoogle Scholar
  39. 39.
    Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B-cells. J Clin Invest 2003; 112:286–297.PubMedGoogle Scholar
  40. 40.
    O’Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199:91–98.PubMedCrossRefGoogle Scholar
  41. 41.
    Jelinek DF, Darce JR. Human B-lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun 2005; 8:266–288.PubMedCrossRefGoogle Scholar
  42. 42.
    Sutherland AP, Mackay F, Mackay CR. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006; 112:774–786.PubMedCrossRefGoogle Scholar
  43. 43.
    Ye Q, Wang L, Wells AD et al. BAFF binding to T-cell-expressed BAFF-R costimulates T-cell proliferation and alloresponses. Eur J Immunol 2004; 34:2750–2759.PubMedCrossRefGoogle Scholar
  44. 44.
    von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278:138–141.CrossRefGoogle Scholar
  45. 45.
    Ng LG, Sutherland AP, Newton R et al. B-cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T-and B-cells. J Immunol 2004; 173:807–817.PubMedGoogle Scholar
  46. 46.
    Sutherland AP, Ng LG, Fletcher CA et al. BAFF augments certain Th 1-associated inflammatory responses. J Immunol 2005; 174:5537–5544.PubMedGoogle Scholar
  47. 47.
    Wang H, Marsters SA, Baker T et al. TACI-ligand interactions are required for T-cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2:632–637.PubMedCrossRefGoogle Scholar
  48. 48.
    Yang M, Hase H, Legarda-Addison D et al. B-cell maturation angigen, the receptor for a proliferation-inducing ligand and B-cell-activating factor of the TNF family, induces antigen presentation in B-cells. J Immunol 2005; 175:2814–2824.PubMedGoogle Scholar
  49. 49.
    Planelles L, Carvalh-Pinto CE, Hardenberg G et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004; 6:399–408.PubMedCrossRefGoogle Scholar
  50. 50.
    Castigli E, Scott S, Dedeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101:3903–3908.PubMedCrossRefGoogle Scholar
  51. 51.
    Varfolomeev E, Kischkel F, Martin F et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24:997–1006.PubMedCrossRefGoogle Scholar
  52. 52.
    Castigli E, Wilson SA, Scott S et al. TACI and BAFF-R mediate isotype switching in B-cells. J Exp Med 2005; 201:35–39.PubMedCrossRefGoogle Scholar
  53. 53.
    Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37:829–834.PubMedCrossRefGoogle Scholar
  54. 54.
    Salzer U, Chapel HM, Webster AD et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37:820–828.PubMedCrossRefGoogle Scholar
  55. 55.
    Khare SD, Sarosi I, Xia XZ et al. Severe B-cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97:3370–3375.PubMedCrossRefGoogle Scholar
  56. 56.
    Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999; 190:1697–1710.PubMedCrossRefGoogle Scholar
  57. 57.
    Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjogren’s syndrome 10.1172/JC1200214121. J Clin Invest 2002; 109:59–68.PubMedGoogle Scholar
  58. 58.
    Zheng Y, Gallucci S, Gaughan JP et al. A role for B-cell-activating factor of the TNF family in chemically induced autoimmunity. J Immunol 2005; 175:6163–6168.PubMedGoogle Scholar
  59. 59.
    Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B-cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; 17:515–524.PubMedCrossRefGoogle Scholar
  60. 60.
    Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B-lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166:6–10.PubMedGoogle Scholar
  61. 61.
    Stohl W, Metyas S, Tan SM et al. B-lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48:3475–3486.PubMedCrossRefGoogle Scholar
  62. 62.
    Matsushita T, Hasegawa M, Yanaba K et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B-lymphocytes. Arthritis Rheum 2006; 54:192–201.PubMedCrossRefGoogle Scholar
  63. 63.
    Cheema GS, Roschke V, Hilbert DM et al. Elevated serum B-lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313–1319.PubMedCrossRefGoogle Scholar
  64. 64.
    Batten M, Fletcher C, Ng LG et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B-cell lymphoma. J Immunol 2004; 172:812–822.PubMedGoogle Scholar
  65. 65.
    Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1065–1067.PubMedCrossRefGoogle Scholar
  66. 66.
    Stohl W, Metyas S, Tan SM et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63:1096–1103.PubMedCrossRefGoogle Scholar
  67. 67.
    Koyama T, Tsukamoto H, Masumoto K et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42:980–985.CrossRefGoogle Scholar
  68. 68.
    Tan SM, Xu D, Roschke V et al. Local production of B-lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 42:982–992.CrossRefGoogle Scholar
  69. 69.
    Takemura S, Braun A, Crowson C et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167:1072–1080.PubMedGoogle Scholar
  70. 70.
    Seyler TM, Park YW, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115:3083–3092.PubMedCrossRefGoogle Scholar
  71. 71.
    Novak AJ, Bram RJ, Kay NE et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100:2973–2979.PubMedCrossRefGoogle Scholar
  72. 72.
    Endo T, Nishio M, Enzler T et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-{kappa}B pathway 10.1182/blood-2006-06-027755. Blood 2007; 109:703–710.PubMedCrossRefGoogle Scholar
  73. 73.
    Chiu A, Xu W, He B et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109:729–739.PubMedCrossRefGoogle Scholar
  74. 74.
    Fu L, Lin-Lee YC, Pham LV et al. Constitutive NF-kappaB and NFAT activation leads to stimualation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006; 107:4540–4548.PubMedCrossRefGoogle Scholar
  75. 75.
    Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell nonHodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104:2247–2253.PubMedCrossRefGoogle Scholar
  76. 76.
    He B, Chadburn A, Jou E et al. Lymphoma B-cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172:3268–3279.PubMedGoogle Scholar
  77. 77.
    Moreaux J, Legouffe E, Jourdan E et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148–3157.PubMedCrossRefGoogle Scholar
  78. 78.
    Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103:689–694.PubMedCrossRefGoogle Scholar
  79. 79.
    Kern C, Cornuel JF, Billard C et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103:679–688.PubMedCrossRefGoogle Scholar
  80. 80.
    Nishio M, Endo T, Tsukada N et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1 alpha. Blood 2005; 106:1012–1020.PubMedCrossRefGoogle Scholar
  81. 81.
    Schwaller J, Schneider P, Mhawech-Fauceglia P et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007; 109:331–338.PubMedCrossRefGoogle Scholar
  82. 82.
    Elsawa SF, Novak AJ, Grote DM et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 2006; 107:2882–2888.PubMedCrossRefGoogle Scholar
  83. 83.
    Ryan MC, Hering M, Peckham D et al. Antibody Targeting of BCMA on Malignant Plasma Cells. Mol Cancer Ther 2007; 6:3007–3018.CrossRefGoogle Scholar
  84. 84.
    Nimmanapalli R, Lyu MA, Du M et al. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 2007; 109:2557–2564.PubMedCrossRefGoogle Scholar
  85. 85.
    Lyu MA, Cheung LH, Hittelman WN et al. The rGel/BLyS fusion toxin specifically targets malignant B-cells expressing the BLyS receptors BAFF-R, TACI and BCMA. Mol Cancer Ther 2007; 6:460–470.PubMedCrossRefGoogle Scholar
  86. 86.
    Kelly K, Manos E, Jensen G et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000; 60:1021–1027.PubMedGoogle Scholar
  87. 87.
    Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2:920–932.PubMedCrossRefGoogle Scholar
  88. 88.
    Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B-lymphocyte stimulator. Arthritis Rheum 2003; 48:3253–3265.PubMedCrossRefGoogle Scholar
  89. 89.
    Parry TJ, Riccobene TA, Strawn SJ et al. Pharmacokinetics and immunological effects of exogenously administered recombinant human B-lymphocyte stimulator (BLyS) in mice. J Pharmacol Exp Ther 2001; 296:396–404.PubMedGoogle Scholar
  90. 90.
    Wallace DJ LJ, Stohl W, McKay J et al. Belimumab (LymphoStat-B) shows bioactivity and reduces SLE disease activity. Belimumab (LymphoStat-B) shows bioactivity and reduces SLE disease activity. European Congress of Rheumatology; 2006.Google Scholar
  91. 91.
    Furie R LJ, Merrill JT, Petri M et al. Multiple SLE disease activity measures in a multi-center Phase 2 SLE trial demonstrate belimumab improves or stabilizes SLE activity in serologically active SLE patients. European Congress of Rheumatology; 2006.Google Scholar
  92. 92.
    Petri M WD, Stohl W, McKay J et al. SLE patients with active production of anti-nuclear auto antibodies (ANA positive) have distinct patterns of lupus activity and peripheral B-cell biomarkers compared to ANA negative patients. European Congress of Rheumatology; 2006.Google Scholar
  93. 93.
    Huizinga T, Boling E, Valente R et al. Genetic and environmental risk factors, disease outcome and responses to anti B-cell therapy belimumab indicate anti-CCP positive RA is a distinct disease entity. 70th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals; 2006.Google Scholar
  94. 94.
    McKay J C-SH, Boling E et al. Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. 69th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals; 2005.Google Scholar
  95. 95.
    Pelletier M, Thompson JS, Qian F et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 2003; 278:33127–33133.PubMedCrossRefGoogle Scholar
  96. 96.
    Vugmeyster Y, Seshasayee D, Chang W et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B-cells and lymphoid tissue marginal zone and follicular B-cells in cynomolgus monkeys. Am J Pathol 2006; 168:476–489.PubMedCrossRefGoogle Scholar
  97. 97.
    Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174:817–826.PubMedGoogle Scholar
  98. 98.
    Lin WY, Gong Q, Seshasayee D et al. Anti-BR3 antibodies—a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 2007. In Press.Google Scholar
  99. 99.
    Patel DR, Wallweber HJ, Yin J et al. Engineering an APRIL-specific B-cell maturation antigen. J Biol Chem 2004; 279:16727–16735.PubMedCrossRefGoogle Scholar
  100. 100.
    Dall’Era M, Chakravarty E, Genovese M et al. Trial of Atacicept in Patients with Systemic Lupus Erythematosus (SLE). American College of Rheumatology; 2006.Google Scholar
  101. 101.
    Tak PP, Thurlings RM, Dimic A et al. A Phase Ib Study to Investigate Atacicept (TACI-Ig) in Patients with Rhuematoid Arthritis. American College of Rheumatolgoy; 2007.Google Scholar
  102. 102.
    Kofler DM, Elter T, Gianella-Borradori A et al. A phase Ib trial of Atacicept (TACI-Ig) to neutralize APRIL and BlyS in patients with refractory or relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL). American Society of Clinical Oncology; 2007.Google Scholar
  103. 103.
    Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724–734.PubMedCrossRefGoogle Scholar
  104. 104.
    Carter RH, Zhao H, Liu X et al. Expression and occupancy of BAFF-R on B-cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52:3943–3954.PubMedCrossRefGoogle Scholar
  105. 105.
    Dillon SR, Gross JA, Ansell SM et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5:235–246.PubMedCrossRefGoogle Scholar
  106. 106.
    Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21:4067–4074.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Maureen C. Ryan
    • 1
  • Iqbal S. Grewal
    • 1
  1. 1.Seattle Genetics, Inc.BothellUSA

Personalised recommendations